The association of serum magnesium and mortality outcomes in heart failure patients: A systematic review and meta-analysis

Medicine (United States)

Volumn 95, Issue 50, 2016, Pages

  Angkananard, Teeranan ^a,b   Anothaisintawee, Thunyarat ^a   Eursiriwan, Sudarat ^a,c   Gorelik, Oleg ^d   McEvoy, Mark ^e   Attia, John ^e   Thakkinstian, Ammarin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Heart failure; Magnesium; Meta analysis; Mortality; Systematic review

Indexed keywords

MAGNESIUM; BIOLOGICAL MARKER; DIURETIC AGENT;

CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERMAGNESEMIA; HYPOMAGNESEMIA; ISCHEMIC HEART DISEASE; MAGNESIUM BLOOD LEVEL; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN DEATH; SYSTEMATIC REVIEW; AGE; AGED; BLOOD; CAUSE OF DEATH; DISEASE COURSE; FEMALE; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SURVIVAL ANALYSIS; VERY ELDERLY; ALL CAUSE MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DOSE RESPONSE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; MEDLINE; MORTALITY RATE; RISK ASSESSMENT; RISK FACTOR; SCOPUS;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 85007508449     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005406     Document Type: Review

References (38)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015;131: E29-322.
2. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013;6: 606-19.
3. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the atherosclerosis risk in communities study). Am J Cardiol 2008;101: 1016-22.
4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128: E240-327.
5. Sanders-van Wijk S, van Asselt ADI, Rickli H, et al. Cost-effectiveness of N-terminal Pro-B-type natriuretic-guided therapy in elderly heart failure patients results from TIME-CHF (trial of intensified versus standard medical therapy in elderly patients with congestive heart failure). JACC Heart Fail 2013;1: 64-71.
6. Cefaratti C, Romani AM. Functional characterization of two distinct Mg (2+) extrusion mechanisms in cardiac sarcolemmal vesicles. Mol Cell Biochem 2007;303: 63-72.
7. Reffelmann T, Ittermann T, Dorr M, et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 2011;219: 280-4.
8. Kolte D, Vijayaraghavan K, Khera S, et al. Role of magnesium in cardiovascular diseases. Cardiol Rev 2014;22: 182-92.
9. Douban S, Brodsky MA, Whang DD, et al. Significance of magnesium in congestive heart failure. Am Heart J 1996;132: 664-71.
10. Lutsey PL, Alonso A, Michos ED, et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2014;100: 756-64.
11. Cohen N, Almoznino-Sarafian D, Zaidenstein R, et al. Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: Pathophysiological correlates and prognostic evaluation. Heart 2003;89: 411-6.
12. Vaduganathan M, Greene SJ, Ambrosy AP, et al. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). Am J Cardiol 2013;112: 1763-9.
13. Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158: 280-6.
14. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8: 1-6.
15. Riley RD, Price MJ, Jackson D, et al. Multivariate meta-analysis using individual participant data. Res Synth Methods 2015;6: 157-74.
16. Gottlieb SS, Baruch L, Kukin ML, et al. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990;16: 827-31.
17. Eichhorn EJ, Tandon PK, DiBianco R, et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: The PROMISE Study. J Am Coll Cardiol 1993;21: 634-40.
18. Madsen BK, Rasmussen V, Hansen JF. Predictors of sudden death and death from pump failure in congestive heart failure are different. Analysis of 24h Holter monitoring, clinical variables, blood chemistry, exercise test and radionuclide angiography. Int J Cardiol 1997;58: 151-62.
19. Corbi G, Acanfora D, Iannuzzi GL, et al. Hypermagnesemia predicts mortality in elderly with congestive heart disease: Relationship with laxative and antacid use. Rejuvenation Res 2008;11: 129-38.
20. Adamopoulos C, Pitt B, Sui X, et al. Low serum magnesium and cardiovascular mortality in chronic heart failure: A propensity-matched study. Int J Cardiol 2009;136: 270-7.
21. Zittermann A, Fuchs U, Kuhn J, et al. Parameters of mineral metabolism predict midterm clinical outcome in end-stage heart failure patients. Scand Cardiovasc J 2011;45: 342-8.
22. Cheungpasitporn W, Thongprayoon C, Qian Q. Dysmagnesemia in hospitalized patients: Prevalence and prognostic importance. Mayo Clin Proc 2015;90: 1001-10.
23. Qu X, Jin F, Hao Y, et al. Magnesium and the risk of cardiovascular events: A meta-analysis of prospective cohort studies. PLoS One 2013;8: E57720.
24. Del Gobbo LC, Imamura F, Wu JH, et al. Circulating and dietary magnesium and risk of cardiovascular disease: A systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2013;98: 160-73.
25. Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: Focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 2012;5: I52-61.
26. Santulli G, Pagano G, Sardu C, et al. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest 2015;125: 1968-78.
27. Sardu C, Carreras G, Katsanos S, et al. Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation. BMC Cardiovasc Disord 2014;14: 176.
28. Li J, Imtiaz MS, Beard NA, et al. ss-Adrenergic stimulation increases RyR2 activity via intracellular Ca2+ and Mg2+ regulation. PLoS One 2013;8: E58334.
29. Vrtovec B, Delgado R, Zewail A, et al. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 2003;107: 1764-9.
30. Clark BA, Brown RS. Unsuspected morbid hypermagnesemia in elderly patients. Am J Nephrol 1992;12: 336-43.
31. Ralston MA, Murnane MR, Unverferth DV, et al. Serum and tissue magnesium concentrations in patients with heart failure and serious ventricular arrhythmias. Ann Intern Med 1990;113: 841-6.
32. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. J Am Coll Cardiol 2014;64: 1143-77.
33. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;1-85.
34. Sardu C, Santamaria M, Rizzo MR, et al. Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): The TELECART Study. Int J Clin Pract 2016;70: 569-76.
35. Petretta M, Colao A, Sardu C, et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007;17: 288-96.
36. Marfella R, Di Filippo C, Potenza N, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: Responders vs. non-responders. Eur J Heart Fail 2013;15: 1277-88.
37. Melman YF, Shah R, Danielson K, et al. Circulating MicroRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: A translational pilot study. Circulation 2015;131: 2202-16.
38. Sardu C, Paolisso G, Marfella R. Letter by Sardu et al regarding article, "Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: A translational pilot study". Circulation 2016;133: E388.